3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
3
Gastrointestinal
2
Lymphoid
1
Head & Neck
1
Dermatologic
1
Breast
1
Conditions
Lymphoma
370
Lymphoma, Non-Hodgkin
348
Leukemia, Lymphocytic, Chronic, B-Cell
322
Precursor Cell Lymphoblastic Leukemia-Lymphoma
291
Lymphoma, Large B-Cell, Diffuse
244
Lymphoma, Follicular
236
Leukemia
198
Hodgkin Disease
171
Lymphoma, Mantle-Cell
164
Leukemia, Myeloid, Acute
160
Multiple Myeloma
134
Myelodysplastic Syndromes
130
Recurrence
125
Burkitt Lymphoma
123
Lymphoma, B-Cell, Marginal Zone
120
Lymphoma, T-Cell, Cutaneous
92
Neoplasms
82
Mycosis Fungoides
82
Lymphoma, B-Cell
82
Waldenstrom Macroglobulinemia
74
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
70
Sezary Syndrome
67
Lymphoma, Large-Cell, Immunoblastic
65
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
57
Lymphoma, Large-Cell, Anaplastic
54
Neoplasms, Plasma Cell
52
Myeloproliferative Disorders
52
Primary Myelofibrosis
46
Hematologic Neoplasms
44
Blast Crisis
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms, Connective and Soft Tissue
×
Lymphoid
×
Clear all
NCT02602067
2018-09-18
Tenatumomab
sigma-tau i.f.r. S.p.A.
Phase 1
Terminated
2 enrolled